Nestlé Health Science Honored with 2024 Innovator Award by BioNJ
Recognized for Pharma innovation and excellence
Nestlé Health Science is honored to have been selected as a 2024 Innovator Award recipient by BioNJ, a New Jersey life sciences trade association, in recognition of our FDA-approved therapeutic in the microbiome space.
The acclaimed Innovator Award honors New Jersey companies that received a new FDA drug approval in 2023. BioNJ is the life sciences trade association for New Jersey, representing close to 400 research-based life sciences organizations across the healthcare ecosystem from the largest biopharmaceutical companies to early stage start-ups for nearly 30 years.
"We are incredibly proud to receive the 2024 Innovator Award from BioNJ, recognizing our FDA-approved therapeutic in the microbiome space and our ongoing commitment to the many communities within New Jersey,” said Moreno Perugini, President of Active & Medical Nutrition, U.S. & President of Global Pharmaceutical Therapies, Nestlé Health Science. “This achievement highlights the dedication and innovation of our Pharma division in addressing the needs of patients suffering from recurrent C.Diff, and reinforces our commitment to making a positive impact in their lives."
Recognized as a respected thought leader, an influential advocate and as sought-after convener of the life sciences industry, BioNJ works directly with legislative leaders in both Trenton and Washington D.C. to advance the life sciences industry, foster medical innovation and ensure health equity and healthcare affordability. With innovation as the driving force behind medical breakthroughs, BioNJ’s mission is to help our members help patients by providing transformative resources, including access to government and industry leaders, capital and state incentives, timely educational programs, skilled talent and a value-driven purchasing program.